- Home
- IVVD vs MCRB Comparison
IVVD vs MCRB Comparison
Compare IVVD & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- MCRB
- Stock Information
- Founded
- IVVD 2020
- MCRB 2010
- Country
- IVVD United States
- MCRB United States
- Employees
- IVVD N/A
- MCRB N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- MCRB Health Care
- Exchange
- IVVD Nasdaq
- MCRB Nasdaq
- Market Cap
- IVVD 69.0M
- MCRB 72.0M
- IPO Year
- IVVD 2021
- MCRB 2015
- Fundamental
- Price
- IVVD $0.75
- MCRB $7.63
- Analyst Decision
- IVVD Strong Buy
- MCRB Hold
- Analyst Count
- IVVD 3
- MCRB 4
- Target Price
- IVVD $5.85
- MCRB $73.67
- AVG Volume (30 Days)
- IVVD 1.8M
- MCRB 75.0K
- Earning Date
- IVVD 08-13-2025
- MCRB 08-12-2025
- Dividend Yield
- IVVD N/A
- MCRB N/A
- EPS Growth
- IVVD N/A
- MCRB N/A
- EPS
- IVVD N/A
- MCRB 8.98
- Revenue
- IVVD $36,688,000.00
- MCRB N/A
- Revenue This Year
- IVVD $446.60
- MCRB N/A
- Revenue Next Year
- IVVD $112.63
- MCRB N/A
- P/E Ratio
- IVVD N/A
- MCRB $0.89
- Revenue Growth
- IVVD N/A
- MCRB N/A
- 52 Week Low
- IVVD $0.35
- MCRB $6.53
- 52 Week High
- IVVD $2.74
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- IVVD 43.27
- MCRB 48.66
- Support Level
- IVVD $0.70
- MCRB $7.25
- Resistance Level
- IVVD $1.03
- MCRB $7.89
- Average True Range (ATR)
- IVVD 0.07
- MCRB 0.46
- MACD
- IVVD -0.03
- MCRB 0.11
- Stochastic Oscillator
- IVVD 12.75
- MCRB 60.23
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.